<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275573</url>
  </required_header>
  <id_info>
    <org_study_id>09 155 02</org_study_id>
    <nct_id>NCT01275573</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease</brief_title>
  <acronym>rTMS</acronym>
  <official_title>High Frequency rTMS (Repetitive Transcranial Magnetic Stimulation) Effect Applied on Primary Cortical Motor, on Nociceptive Perception Thresholds in Parkinson's Disease Patients: a Physiopathology Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is a frequent symptom in Parkinson's disease. Previous studies have shown that pain&#xD;
      perception was altered in Parkinson's disease patients and could be related to nociceptive&#xD;
      cortical area hyperactivation. Repetitive Transcranial Magnetic Stimulation is an&#xD;
      electrophysiological tool which can modify cortical excitability. Its efficacy was&#xD;
      demonstrated in neuropathic pain. This is a randomized, double blind cross-over study. In&#xD;
      this study, subjective pain threshold (using thermal stimulation (Thermotest)).will be&#xD;
      evaluated in 3 groups of subjects: healthy volunteers, painful Parkinson's patients and pain&#xD;
      free Parkinson's disease patients. Each group will receive a high frequency Repetitive&#xD;
      Transcranial Magnetic Stimulation and placebo stimulation in different order with a gap of&#xD;
      one week.&#xD;
&#xD;
      The investigators supposed that a 20 Hz Repetitive Transcranial Magnetic Stimulation session&#xD;
      with an infraliminary intensity on the primary cortical motor, modulating nociceptive&#xD;
      cortical areas activity, could modify the nociceptive threshold perception in Parkinson's&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of subjective pain threshold determined using thermal stimulation (Thermotest) with the method of levels after rTMS session</measure>
    <time_frame>D1 T0, D1 T1h30mn, D7 T0, D7 T1h30mn</time_frame>
    <description>Change from baseline after each Repetitive Transcranial Magnetic Stimulation session (active and placebo)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic effect of Repetitive Transcranial Magnetic Stimulation using Visual Analogue Scale</measure>
    <time_frame>D1 T0, D1 T1h30mn, D7 T0, D7 T1h30mn</time_frame>
    <description>Change from baseline after each Repetitive Transcranial Magnetic Stimulation session (active and placebo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Clinical evaluation of the severity of the motor handicap of patients using Unified's Parkinson's Disease Rating Scale (UPDRSIII)</measure>
    <time_frame>D1 T0, D1 T1h30mn, D7 T0, D7 T1h30mn</time_frame>
    <description>Change from baseline after each Repetitive Transcranial Magnetic Stimulation session (active and placebo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood assessment using Visual Analogue Scale</measure>
    <time_frame>D1 T0, D1 T1h30mn, D7 T0, D7 T1h30mn</time_frame>
    <description>Change from baseline after each Repetitive Transcranial Magnetic Stimulation session (active and placebo)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>painful Parkinson's disease patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>painless Parkinson's disease patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>painful Parkinson's disease patients</arm_group_label>
    <arm_group_label>painless Parkinson's disease patients</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patients:&#xD;
&#xD;
          -  Patients with clinical diagnosis of Parkinson's disease according to the criteria of&#xD;
             the UKPDSBB&#xD;
&#xD;
          -  Parkinson's disease patients with a score≤3 on the Hoehn and Year scale&#xD;
&#xD;
          -  Patients treated with dopaminergic antiparkinsonian drugs (L-DOPA, dopamine&#xD;
             agonists,ICOMT…)&#xD;
&#xD;
          -  Patients with or without neuropathic pain induced by Parkinson's disease&#xD;
&#xD;
          -  Patients without personal or familial epilepsy episode history&#xD;
&#xD;
          -  Patients from 50 to 80 years old (male or female)&#xD;
&#xD;
          -  Patients affiliated to a social protection program&#xD;
&#xD;
          -  Patient with an informed consent given&#xD;
&#xD;
        For Healthy volunteers&#xD;
&#xD;
          -  Subjects from 50 to 80 years old (male or female)&#xD;
&#xD;
          -  Subjects without any serious evolutionary pathology or any clinical significant&#xD;
             treatment&#xD;
&#xD;
          -  Subjects without chronic pain or disease which can induce neuropathic pain&#xD;
&#xD;
          -  Subjects without personal or familial epilepsy episode history&#xD;
&#xD;
          -  Subjects affiliated to a social protection program&#xD;
&#xD;
          -  Subjects with an informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For patients:&#xD;
&#xD;
          -  Patients suffering from an other pathology causing chronic pain (rheumatic disease,&#xD;
             traumatic or orthopaedic pathologies…)&#xD;
&#xD;
          -  Parkinson's disease patients with a score&gt;3 on the Hoehn and Yahr scale&#xD;
&#xD;
          -  Patients with important tremors during a OFF conditions&#xD;
&#xD;
          -  Patients suffering from a cancer&#xD;
&#xD;
          -  Patients with a neuroleptic treatment&#xD;
&#xD;
          -  Patients under tutelage, curatella or law protection&#xD;
&#xD;
          -  Patients included in an other clinical study&#xD;
&#xD;
          -  Patients unable to fulfil scales of the study&#xD;
&#xD;
          -  Patients with personal or familial epilepsy episode history&#xD;
&#xD;
          -  Contraindication of IRM&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
        For Healthy volunteers:&#xD;
&#xD;
          -  Subjects with serious evolutionary pathology or any clinical significant treatment&#xD;
&#xD;
          -  Subjects with chronic pain or disease which can induce neuropathic pain&#xD;
&#xD;
          -  Subjects with personal or familial epilepsy episode history&#xD;
&#xD;
          -  Contraindication of IRM&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Subjects under tutelage, curatella or law protection&#xD;
&#xD;
          -  Subjects included in an other clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Brefel-Courbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Purpan Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>pain threshold</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Pain threshold in Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

